Loading stock data…
QTTB
$5.04-0.56 (-10.00%)
Market ClosedLast close May 1
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Q32 Bio Inc. in the Healthcare sector is trading at $5.04. The stock is currently 37% below its 52-week high of $8.04, remaining 44.0% above its 200-day moving average. Technical signals show neutral RSI of 46 and bearish MACD signal, explaining why QTTB maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 46) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.04
Potential Upside
1102.4%
Whystock Fair Value$60.60
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Buy
Mean target$14.33+184.4%
Range$10.00 – $20.00
Fundamentals
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$94.80M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
2.68
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.02
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
70.98%
Volume
Today's trading volume
288,482
Recent News
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?
QTTB heads into Q1 earnings with investors eyeing bempikibart updates, as the SIGNAL-AA study progresses with data due in mid-2026.
Does Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect?
The consensus price target hints at a 97.7% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Best Momentum Stocks to Buy for March 27th
MGY, ESCA, and QTTB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 27, 2026.
New Strong Buy Stocks for March 27th
DNN, CM, MGY, QTTB and FLXS have been added to the Zacks Rank #1 (Strong Buy) List on March 27, 2026.
Q32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should Know
Q32 Bio (QTTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).